Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.
Daniel WattersonDanushka K WijesundaraNaphak ModhiranFrancesca L MordantZheyi LiMichael S AvumegahChristopher Ld McMillanJulia LackenbyKate GuilfoyleGeert van AmerongenKoert StittelaarStacey Tm CheungSumma BibbyMallory DalerisKym HogerMarianne GillardEve RadunzMartina L JonesKaren HughesBen HughesJustin GohDavid EdwardsJudith ScobleLesley PearceLukasz KowalczykTram PhanMylinh LaLouis LuTam PhamQi ZhouDavid A BrockmanSherry J MorganCora LauMai H TranPeter TapleyFernando Villalón-LetelierJames BarnesAndrew YoungNoushin JaberolansarConnor Ap ScottAriel IsaacsAlberto A AmarillaAlexander A KhromykhJudith Ma van den BrandPatrick C ReadingCharani RanasingheKanta SubbaraoTrent P MunroPaul R YoungKeith J ChappellPublished in: Clinical & translational immunology (2021)
The SARS-CoV-2 Sclamp vaccine candidate is compatible with large-scale commercial manufacture, stable at 2-8°C. When formulated with MF59 adjuvant, it elicits neutralising antibodies and T-cell responses and provides protection in animal challenge models.